Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for HER2-Positive Breast Cancer

Shots:

• The P-III FeDeriCa study involves assessing of SC inj. of Perjeta + Herceptin + CT vs IV infusion of Perjeta + Herceptin + CT in 500 patients with HER2+ who are being treated in the neoadjuvant and adjuvant setting
• The P-III FeDeriCa study results: met its 1EP & 2EPs i.e, minimum levels of Perjeta & Herceptin in the blood during a given dosing interval (C_trough); the rate of pCR (59.7% vs 59.5%); no new safety signals were identified with no difference in cardiac toxicity respectively
• The FDC of Perjeta and Herceptin is a new SC formulation combining the Perjeta and Herceptin with Halozyme’s Enhanze drug delivery technology, administered under the skin in just minutes compared to hours with IV administration thus reducing the time spent in receiving treatment

Click here to­ read full press release/ article | Ref: Roche | Image: Biospace